Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$174 Mln
P/E Ratio
51.17
P/B Ratio
2.79
Industry P/E
87.38
Debt to Equity
0
ROE
0.06 %
ROCE
--
Div. Yield
0 %
Book Value
1.66
EPS
--
CFO
$-34.26 Mln
EBITDA
$-49.00 Mln
Net Profit
$-66.28 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
BrainsWay - ADR
| -2.33 | -5.73 | -13.84 | 83.10 | 5.97 | 3.38 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
BrainsWay - ADR
| 45.08 | 162.35 | -67.92 | 2.12 | -22.67 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 24.96 | 1,186.57 | -- | 0.74 | |
| 123.41 | 4,306.02 | 57.4 | 4.76 | |
| 94.61 | 5,591.89 | 46.38 | 8.89 | |
| 299.78 | 11,550.00 | 278.74 | 3.65 |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of... major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel. Read more
Chief Executive Officer
Mr. Hadar Levy
Chief Executive Officer
Mr. Hadar Levy
Headquarters
Jerusalem
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of BrainsWay Ltd - ADR stood at $ 174 Mln as on 31-Mar-25
The share price of BrainsWay Ltd - ADR is $9.21 (NASDAQ) as of 25-Apr-2025 16:00 EDT. BrainsWay Ltd - ADR has given a return of 5.97% in the last 3 years.
BrainsWay Ltd - ADR has a market capitalisation of $ 174 Mln as on 25-Apr-2025. As per Value Research classification, it is a company.
The P/B ratio of BrainsWay Ltd - ADR is 2.79 times as on 25-Apr-2025, a 22% discount to its peers’ median range of 3.59 times.
The P/E ratio of BrainsWay Ltd - ADR is 51.17 times as on 25-Apr-2025, a 41% discount to its peers’ median range of 87.38 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BrainsWay Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of BrainsWay Ltd - ADR.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
The CEO & director of Mr. Hadar Levy. is BrainsWay Ltd - ADR, and CFO & Sr. VP is Mr. Hadar Levy.
There is no promoter pledging in BrainsWay Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
537
|
|
|
420
|
|
|
116
|
| BrainsWay Ltd. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
8.2
|
|
Operating margin(%)
|
5.91
|
|
Net Margin(%)
|
10.06
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of BrainsWay Ltd - ADR was $0 Mln.
$0.09
(
